IVACAFTOR and COUGH

Overview

COUGH is the #8 most commonly reported adverse reaction for IVACAFTOR, manufactured by Vertex Pharmaceuticals Incorporated. There are 219 FDA adverse event reports linking IVACAFTOR to COUGH. This represents approximately 2.4% of all 9,200 adverse event reports for this drug.

Patients taking IVACAFTOR who experience cough should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

COUGH is a less commonly reported adverse event for IVACAFTOR, but still significant enough to appear in the safety profile.

Other Side Effects of IVACAFTOR

In addition to cough, the following adverse reactions have been reported for IVACAFTOR:

• HOSPITALISATION — 1,286 reports
• INFECTIVE PULMONARY EXACERBATION OF CYSTIC FIBROSIS — 601 reports
• PNEUMONIA — 262 reports
• INFECTION — 249 reports
• MALAISE — 247 reports
• LOWER RESPIRATORY TRACT INFECTION — 242 reports
• DEATH — 224 reports
• CYSTIC FIBROSIS — 211 reports
• HEADACHE — 194 reports
• NASOPHARYNGITIS — 168 reports

Other Drugs Associated with COUGH

The following drugs have also been linked to cough in FDA adverse event reports:

Does IVACAFTOR cause COUGH?

COUGH has been reported as an adverse event in 219 FDA reports for IVACAFTOR. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is COUGH with IVACAFTOR?

COUGH accounts for approximately 2.4% of all adverse event reports for IVACAFTOR, making it a notable side effect.

What should I do if I experience COUGH while taking IVACAFTOR?

If you experience cough while taking IVACAFTOR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages